Literature DB >> 24186894

Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosis.

Junfeng Xiao1, Yi Zhao, Rency S Varghese, Bin Zhou, Cristina Di Poto, Lihua Zhang, Mahlet G Tadesse, Dina Hazem Ziada, Kirti Shetty, Habtom W Ressom.   

Abstract

BACKGROUND: The effects of hepatocellular carcinoma on liver metabolism and circulating metabolites have been subjected to continuing investigation. This study compares the levels of selected metabolites in sera of hepatocellular carcinoma cases versus patients with liver cirrhosis and evaluates the influence of gender, race, and alcoholic cirrhosis on the performance of the metabolites as candidate biomarkers for hepatocellular carcinoma.
METHODS: Targeted quantitation of 15 metabolites is performed by selected research monitoring in sera from 89 Egyptian subjects (40 hepatocellular carcinoma cases and 49 cirrhotic controls) and 110 U.S. subjects (56 hepatocellular carcinoma cases and 54 cirrhotic controls). Logistic regression models are used to evaluate the ability of these metabolites in distinguishing hepatocellular carcinoma cases from cirrhotic controls. The influences of gender, race, and alcoholic cirrhosis on the performance of the metabolites are analyzed by stratified logistic regression.
RESULTS: Two metabolites are selected on the basis of their significance to both cohorts. Although both metabolites discriminate hepatocellular carcinoma cases from cirrhotic controls in males and Caucasians, they are insignificant in females and African Americans. One metabolite is significant in patients with alcoholic cirrhosis and the other in nonalcoholic cirrhosis.
CONCLUSIONS: The study demonstrates the potential of two metabolites as candidate biomarkers for hepatocellular carcinoma by combining them with α-fetoprotein (AFP) and gender. Stratified statistical analyses reveal that gender, race, and alcoholic cirrhosis affect the relative levels of small molecules in serum. IMPACT: The findings of this study contribute to a better understanding of the influence of gender, race, and alcoholic cirrhosis in investigating small molecules as biomarkers for hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24186894      PMCID: PMC3947117          DOI: 10.1158/1055-9965.EPI-13-0327

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma.

Authors:  H S Lee; Y H Chung; C Y Kim
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.

Authors:  E Ellen Schwegler; Lisa Cazares; Laura F Steel; Bao-Ling Adam; David A Johnson; O John Semmes; Timothy M Block; Jorge A Marrero; Richard R Drake
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

4.  Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.

Authors:  Faten Charni; Angela Sutton; Pierre Rufat; Christelle Laguillier; Abdellah Mansouri; Richard Moreau; Nathalie Ganne-Carrié; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Charnaux; Pierre Nahon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-24       Impact factor: 4.254

5.  Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.

Authors:  Baohong Wang; Deying Chen; Yu Chen; Zhenhua Hu; Min Cao; Qing Xie; Yanfei Chen; Jiali Xu; Shusen Zheng; Lanjuan Li
Journal:  J Proteome Res       Date:  2012-01-18       Impact factor: 4.466

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

7.  Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.

Authors:  Mindie H Nguyen; Ruel T Garcia; Peter W Simpson; Teresa L Wright; Emmet B Keeffe
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

8.  Epidemiology, risk factors, and natural history of hepatocellular carcinoma.

Authors:  Giuseppe Montalto; Melchiorre Cervello; Lydia Giannitrapani; Fabio Dantona; Angela Terranova; Luigi A M Castagnetta
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

9.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

10.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

View more
  6 in total

1.  Conditional independence test by generalized Kendall's tau with generalized odds ratio.

Authors:  Shuang Ji; Jing Ning; Jing Qin; Dean Follmann
Journal:  Stat Methods Med Res       Date:  2017-02-23       Impact factor: 3.021

2.  GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort.

Authors:  Mohammad R Nezami Ranjbar; Yue Luo; Cristina Di Poto; Rency S Varghese; Alessia Ferrarini; Chi Zhang; Naglaa I Sarhan; Hanan Soliman; Mahlet G Tadesse; Dina H Ziada; Rabindra Roy; Habtom W Ressom
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

Review 3.  Metabolomic Approaches in Cancer Epidemiology.

Authors:  Mukesh Verma; Hirendra Nath Banerjee
Journal:  Diseases       Date:  2015-08-11

4.  Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.

Authors:  Cristina Di Poto; Shisi He; Rency S Varghese; Yi Zhao; Alessia Ferrarini; Shan Su; Abdullah Karabala; Mesfin Redi; Hassen Mamo; Amol S Rangnekar; Thomas M Fishbein; Alexander H Kroemer; Mahlet G Tadesse; Rabindra Roy; Zaki A Sherif; Deepak Kumar; Habtom W Ressom
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

5.  Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Mathias Gehrmann; Melchiorre Cervello; Giuseppe Montalto; Francesco Cappello; Alessandro Gulino; Clemens Knape; Hanno M Specht; Gabriele Multhoff
Journal:  Front Immunol       Date:  2014-07-01       Impact factor: 7.561

6.  Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues.

Authors:  Israa T Ismail; Oliver Fiehn; Ashraf Elfert; Marwa Helal; Ibrahim Salama; Hala El-Said
Journal:  Cancers (Basel)       Date:  2020-02-19       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.